RGD Peptide Side Effects: Safety Signals and Warnings
RGD Peptide safety concerns are compound-specific. The main listed side effects are Generally well-tolerated as biomaterial component, Cilengitide: fatigue, nausea, lymphopenia, and Potential to inhibit platelet aggregation at high systemic doses. The main warning signals are Linear RGD has very short in vivo half-life and limited standalone therapeutic utility, Cyclic RGD variants have more clinical relevance but mixed efficacy results, and High systemic doses may interfere with normal integrin-mediated processes (platelet adhesion, wound healing).
Direct Answer
Evidence for RGD peptide as a standalone therapeutic is too preliminary to support a research protocol with confidence. RGD is an integrin-binding motif extensively used as a biomaterials scaffold component, but direct therapeutic administration has minimal clinical evidence. Its value is primarily as a cell-adhesion-promoting coating in regenerative medicine scaffolds, not as a systemic therapeutic.
- Evidence grade
- Level C
- Research status
- Preclinical
- Category
- Anti-Aging & Longevity
- Best for
- Biomaterials research, integrin-binding mechanistic studies, cell adhesion scaffolding
Reported Side Effects
- Generally well-tolerated as biomaterial component
- Cilengitide: fatigue, nausea, lymphopenia
- Potential to inhibit platelet aggregation at high systemic doses
Warnings
- Linear RGD has very short in vivo half-life and limited standalone therapeutic utility
- Cyclic RGD variants have more clinical relevance but mixed efficacy results
- High systemic doses may interfere with normal integrin-mediated processes (platelet adhesion, wound healing)
Known or Plausible Interactions
- Anticoagulants (RGD can inhibit integrin alpha-IIb-beta-3 on platelets)
- Anti-angiogenic drugs (potential synergy with cyclic RGD variants)
- ECM-derived peptides (complementary in tissue engineering)
Regulatory Context
Research reagent; cyclic variants (cilengitide) reached Phase 3 clinical trials but not FDA-approved.
Evidence Snapshot
| Evidence grade | Level C |
|---|---|
| Research status | Preclinical |
| Best supported outcomes | Cell Adhesion Enhancement (Level B), Wound Healing Scaffold Performance (Level C), and Anti-Angiogenic Effects (cyclic RGD) (Level C) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "RGD Peptide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/rgd-peptide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.